Total Payments
$1,592
2024 Payments
$493.42
Companies
30
Transactions
72
Medicare Patients
692
Medicare Billing
$49,678
Payment Breakdown by Category
Food & Beverage$1,126 (70.7%)
Education$465.80 (29.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,126 | 64 | 70.7% |
| Education | $465.80 | 8 | 29.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $153.64 | 9 | $0 (2024) |
| PFIZER INC. | $152.99 | 8 | $0 (2024) |
| Lilly USA, LLC | $116.54 | 1 | $0 (2018) |
| ABBVIE INC. | $113.52 | 6 | $0 (2024) |
| Seagen Inc. | $99.99 | 1 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $99.95 | 1 | $0 (2022) |
| Daiichi Sankyo Inc. | $94.55 | 4 | $0 (2024) |
| Incyte Corporation | $90.95 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $64.79 | 4 | $0 (2024) |
| Gilead Sciences, Inc. | $60.33 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $493.42 | 20 | Daiichi Sankyo Inc. ($94.55) |
| 2023 | $190.95 | 10 | PFIZER INC. ($39.73) |
| 2022 | $461.72 | 19 | Seagen Inc. ($99.99) |
| 2021 | $61.50 | 4 | Global Blood Therapeutics, Inc. ($17.06) |
| 2020 | $14.91 | 1 | Merck Sharp & Dohme Corporation ($14.91) |
| 2019 | $242.26 | 16 | Janssen Biotech, Inc. ($33.03) |
| 2018 | $127.23 | 2 | Lilly USA, LLC ($116.54) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Oncology | ||||||
| 12/02/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.47 | General |
| 07/10/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $28.39 | General |
| Category: HORMONE THERAPY | ||||||
| 07/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Oncology | ||||||
| 05/20/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $37.83 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $90.95 | General |
| 04/15/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Iron Deficiency Anemia | ||||||
| 01/08/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: HORMONE THERAPY | ||||||
| 11/29/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.28 | General |
| 09/18/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $23.80 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 123 | 185 | $19,958 | $7,486 |
| 2022 | 4 | 140 | 200 | $22,884 | $9,424 |
| 2021 | 4 | 161 | 242 | $24,966 | $10,949 |
| 2020 | 9 | 268 | 476 | $57,028 | $21,819 |
Total Patients
692
Total Services
1,103
Medicare Billing
$49,678
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 78 | 132 | $14,484 | $5,429 | 37.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 17 | 22 | $3,500 | $1,357 | 38.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 28 | 31 | $1,974 | $700.65 | 35.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 81 | 133 | $14,077 | $6,184 | 43.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 18 | 24 | $3,684 | $1,605 | 43.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $3,228 | $940.57 | 29.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 29 | 31 | $1,895 | $695.06 | 36.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 63 | 109 | $11,113 | $5,179 | 46.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 26 | 36 | $5,274 | $2,579 | 48.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 58 | 83 | $4,923 | $1,868 | 37.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 14 | 14 | $3,656 | $1,324 | 36.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 76 | 186 | $18,218 | $6,858 | 37.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 27 | 45 | $6,324 | $2,450 | 38.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 20 | 22 | $5,720 | $2,324 | 40.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 13 | $5,005 | $1,989 | 39.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 34 | $4,692 | $1,870 | 39.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 18 | 18 | $4,522 | $1,717 | 38.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 16 | 52 | $3,900 | $1,570 | 40.3% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 66 | 87 | $4,999 | $1,563 | 31.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 18 | 19 | $3,648 | $1,478 | 40.5% |
About Dr. David Nixon, M.D
Dr. David Nixon, M.D is a Hematology & Oncology healthcare provider based in Jonesboro, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700846045.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Nixon, M.D has received a total of $1,592 in payments from pharmaceutical and medical device companies, with $493.42 received in 2024. These payments were reported across 72 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($1,126).
As a Medicare-enrolled provider, Nixon has provided services to 692 Medicare beneficiaries, totaling 1,103 services with total Medicare billing of $49,678. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Jonesboro, AR
- Active Since 03/23/2006
- Last Updated 11/03/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700846045
Products in Payments
- KEYTRUDA (Biological) $135.22
- CYRAMZA (Drug) $116.54
- ELITEK (Biological) $99.95
- VENCLEXTA (Drug) $83.92
- IBRANCE (Drug) $76.58
- Enhertu (Drug) $73.82
- BRUKINSA (Drug) $55.10
- IMBRUVICA (Drug) $54.22
- ORGOVYX (Drug) $53.18
- XTANDI (Drug) $51.15
- ZEJULA (Drug) $39.16
- CABOMETYX (Drug) $34.30
- Nerlynx (Drug) $33.01
- Lenvima (Drug) $32.51
- DARZALEX (Biological) $31.76
- Venclexta (Drug) $29.60
- XPOVIO (Drug) $23.80
- INJECTAFER (Drug) $20.73
- PADCEV (Drug) $17.44
- ULTOMIRIS (Drug) $17.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Jonesboro
Mazen Khalil, M.d, M.D
Hematology & Oncology — Payments: $35,868
Hematology & Oncology $35,868
Carroll Scroggin, M.d, M.D
Hematology & Oncology — Payments: $5,714
Hematology & Oncology $5,714
Dr. Scott Dorroh, Md, MD
Hematology & Oncology — Payments: $5,326
Hematology & Oncology $5,326
Sandra Kang, Md, MD
Hematology & Oncology — Payments: $764.54
Hematology & Oncology $764.54
Michael Doherty, Md, MD
Hematology & Oncology — Payments: $443.65
Hematology & Oncology $443.65
Shefali Shah, Md, MD
Hematology & Oncology — Payments: $204.47
Hematology & Oncology $204.47